Literature DB >> 7606718

Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3.

M Negrini1, D Rasio, G M Hampton, S Sabbioni, S Rattan, S L Carter, A L Rosenberg, G F Schwartz, Y Shiloh, W K Cavenee.   

Abstract

Chromosome 11 is frequently altered in several types of human neoplasms. In breast cancer, loss of heterozygosity has been described in two regions of this chromosome, 11p15 and 11q22-23. In this report we have dissected the two regions using high-density polymorphic markers, and have found that there are at least two independent areas of loss of heterozygosity in each region, suggesting that multiple genes on chromosome 11 may be targets of genetic alteration during tumor establishment or progression. The regions defined are: at 11p15, between loci D11S576 and D11S1318 and between D11S988 and D11S1318; at 11q23, between D11S2000 and D11S897 and between D11S528 and D11S990. The narrowing of these regions of loss should facilitate the cloning of the regions in yeast artificial chromosomes to identify the critical tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606718

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Cloning, expression and localization of human BM88 shows that it maps to chromosome 11p15.5, a region implicated in Beckwith-Wiedemann syndrome and tumorigenesis.

Authors:  M Gaitanou; P Buanne; C Pappa; N Georgopoulou; A Mamalaki; F Tirone; R Matsas
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

Review 2.  Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Evi Lianidou; Zissimos Mourelatos
Journal:  RNA       Date:  2009-06-26       Impact factor: 4.942

3.  The long and short of chromosome 11 in breast cancer.

Authors:  I F Newsham
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

4.  Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway.

Authors:  H Nakanishi; C Taccioli; J Palatini; C Fernandez-Cymering; R Cui; T Kim; S Volinia; C M Croce
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

5.  Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis.

Authors:  E K Goldberg; J M Glendening; Z Karanjawala; A Sridhar; G J Walker; N K Hayward; A J Rice; D Kurera; Y Tebha; J W Fountain
Journal:  Am J Hum Genet       Date:  2000-07-29       Impact factor: 11.025

6.  Alterations of ATM and CADM1 in chromosomal 11q22.3-23.2 region are associated with the development of invasive cervical carcinoma.

Authors:  Dipanjana Mazumder Indra; Sraboni Mitra; Anup Roy; Ranajit Kumar Mondal; Partha Sarathi Basu; Susanta Roychoudhury; Runu Chakravarty; Chinmay Kumar Panda
Journal:  Hum Genet       Date:  2011-06-05       Impact factor: 4.132

7.  Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer.

Authors:  Parvin Mehdipour; Marzieh Mahdavi; Javad Mohammadi-Asl; Morteza Atri
Journal:  Med Oncol       Date:  2010-04-16       Impact factor: 3.064

8.  Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26.

Authors:  Ziad J Sahab; Michael D Hall; Lihua Zhang; Amrita K Cheema; Stephen W Byers
Journal:  J Cancer       Date:  2010-06-02       Impact factor: 4.207

9.  The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene.

Authors:  Eric S Martin; Rossano Cesari; Francesca Pentimalli; Kristine Yoder; Richard Fishel; Andrew L Himelstein; S Eric Martin; Andrew K Godwin; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

10.  MicroRNAs as Novel Biomarkers for Breast Cancer.

Authors:  H M Heneghan; N Miller; A J Lowery; K J Sweeney; M J Kerin
Journal:  J Oncol       Date:  2009-07-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.